Percutaneous Coronary Intervention Complexity and Risk of Adverse Events in relation to High Bleeding Risk among Patients Receiving Drug-Eluting Stents: Insights from a Large Single-Center Cohort Study

Table 3

HRs for adverse events associated with complex PCI stratified by PARIS bleeding risk score.

	PARIS bleeding risk score<8 (non-HBR)			PARIS bleeding risk score≥8 (HBR)
	Complex PCI (n = 3479)	Noncomplex PCI (n = 6218)	Adjusted HR (95% CI)	Complex PCI (n = 172)	Noncomplex PCI (n = 298)	Adjusted HR (95% CI)	value for interaction
MACE^a	265 (7.6%)	270 (4.3%)	1.66 (1.40–1.97)	15 (8.7%)	20 (6.7%)	1.13 (0.57–2.25)	0.388
Death	45 (1.3%)	64 (1.0%)	1.30 (0.87–1.93)	9 (5.2%)	15 (5.0%)	0.83 (0.33–2.11)	0.496
Cardiac death	26 (0.7%)	29 (0.5%)	1.63 (0.94–2.84)	7 (4.1%)	9 (3.0%)	1.15 (0.37–3.58)	0.519
MI	101 (2.9%)	80 (1.3%)	2.19 (1.62–2.95)	8 (4.7%)	7 (2.3%)	1.57 (0.51–4.83)	0.720
Definite/probable ST	39 (1.3%)	21 (0.5%)	3.14 (1.83–5.39)	5 (2.9%)	6 (2.0%)	1.42 (0.38–5.29)	0.146
TLR	175 (5.0%)	182 (2.9%)	1.59 (1.29–1.97)	7 (4.1%)	8 (2.7%)	1.52 (0.51–4.46)	0.886
Clinically relevant bleeding^b	77 (2.2%)	178 (2.9%)	0.82 (0.62–1.07)	10 (5.8%)	13 (4.4%)	1.22 (0.52–2.85)	0.279

Values are number of events (%) unless otherwise indicated. The following covariates have been included in the Cox regression multivariable model: age, sex, current smoking, body mass index, hypertension, diabetes mellitus, chronic kidney disease, left ventricular ejection fraction, prior MI, prior revascularization (percutaneous coronary intervention and/or coronary artery bypass graft), acute coronary syndrome, mean stent diameter, hemoglobin, platelet count, type of DES implanted, and DAPT duration (as a time-adjusted covariate). Abbreviations as in Table 1 and Table 2^a MACE was defined as the composite of cardiac death, myocardial infarction, definite/probable stent thrombosis, or target lesion revascularization. ^b Clinically relevant bleeding was defined as BARC type 2, 3, or 5.